10-羧基-2-癸烯酸及蜂王浆防治大鼠肝纤维化的实验研究  

Experimental study of 10-HDA and royal jelly on hepatic fibrosis in rats

作　　者：茹清静[1,2] 施维群[2] 李天一[1] 章亮[2] 徐珊[1] 

机构地区：[1]浙江中医药大学,浙江杭州310005 [2]浙江中医药大学附属第二医院肝病中心

出　　处：《中西医结合肝病杂志》2010年第3期168-170,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：浙江省医药卫生科学研究基金资助项目(No.2004B146)

摘　　要：目的:观察蜂王浆及其主要活性成分癸烯酸防治大鼠肝纤维化的疗效及机制。方法:采用四氯化碳(CCl4)诱导中度肝纤维化模型大鼠,使用10-羧基-2-癸烯酸(10-HDA)(ig,100mg·kg-1·d-1,共12周)和蜂王浆(ig,1000mg·kg-1·d-1·12w)分别在造模开始前和造模完成后干预,并设立模型对照组、正常对照组。分别测定治疗后大鼠血清丙氨酸氨基转移酶(ALT)、透明质酸(HA)、Ⅲ型前胶原肽(PⅢP)、层粘蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、血清转化生长因子-β1(TGF-β1),光镜观察肝组织病理形态学变化。结果:①在肝纤维化预防组,癸烯酸组和蜂王浆组对造模大鼠血清ALT水平的降低与模型对照组比较,差异均无显著性意义(P>0.05);但在肝纤维化治疗组,血清ALT水平的降低有显著性意义(P<0.01)。而在两大组内癸烯酸组和蜂王浆组之间血清ALT水平的降低无显著性差异(P>0.05)。②在肝纤维化预防组和肝纤维化治疗组中癸烯酸组和蜂王浆组大鼠血清Ⅳ-C、PⅢP、LN、HA和TGF-β1的降低与模型对照组比较,差异均有显著性意义(P<0.01),而癸烯酸组和蜂王浆组之间的差异则无显著性意义(P>0.05)。③肝纤维化预防组大鼠肝脏炎症和纤维化程度均低于模型对照组,差异有统计学意义(P<0.05);肝纤维化治疗组大鼠肝脏炎症低于模型对照组(P<0.05),但大鼠肝脏纤维化程度与模型对照组比较,其差异无显著性意义。结论:癸烯酸和蜂王浆对CCl4肝纤维化大鼠的肝脏纤维化血清学指标及肝脏病理形态学均具有显著的改善作用,但对已经形成肝纤维化后的肝组织纤维化改善不明显,且癸烯酸和蜂王浆两者之间的疗效差异无显著性意义。其可能的机制为癸烯酸加蜂王浆能改善肝组织的炎症、减少ECM的合成和抑制TGF-β1的分泌。Objective：To investigate preventive effect of 10-HDA and royal jelly on hepatic fibrosis in rats as well as their relative mechanisms.Methods：Hepatic fibrosis in rats was induced by CCl4 and 10-HDA and royal jelly was given before and after model establishment.The administration of the two formulas lasted for 12 weeks.Then serum lever of ALT and Ⅳ-C、PⅢP、LN、HA and TGFβ1 were determined and histopathological changes were observed by optical microscopy.Results：①ALT in the serum were obviously higher in model group than in therapeutic group（P0.01）,but no significantly reduced in preventive group（P0.05）;②Ⅳ-C、PⅢP、LN、HA and TGF-β1 in the serum were lower in both preventive group and therapeutic group than in model group（P0.01）,It’s no remarkable difference between 10-HDA group and royal jelly group;③The rats liver inflammation and the fibrosis degree were lower than the model group in preventive group（P0.05）;The hepatic fibrosis therapeutic group liver inflammation was lower than the model group,but the fibrosis degree not significantly improved compares with the model group.It’s no remarkable difference between 10-HDA group and royal jelly group too.Conclusion：Ten-HDA and royal jelly both has remarkably therapeutic effects in serology target and the pathology morphology on hepatic fibrosis of rats,but it is no remarkable effect when the hepatic fibrosis already formed.The efficacy between 10-HDA and royal jelly not remarkable difference.its possible mechanism to improve the inflammation in the liver organizes,reduces the synthesis of ECM and suppresses secretion of TGF-β1.

关 键 词：肝纤维化 癸烯酸 蜂王浆 治疗 转化生长因子-Β1 

分 类 号：R285[医药卫生—中药学]